The medication is commonly used across conditions characterized by periods of heightened symptoms within the therapeutic domains of Epileptology and Neuropsychiatry.

The treatment is applied in addressing various seizure disorders, including generalized and partial seizures, and is also relevant for the treatment and prophylaxis of Bipolar Disorder. In these clinical settings, the treatment helps address symptom clusters that may become intense or disruptive by managing the symptoms of increased neurological activity or extreme emotional volatility. The treatment is relevant when supportive symptom management is appropriate.

“The treatment is commonly used when short-term symptomatic assistance is needed, and the formulation is relevant in contexts involving heightened systemic burden.”

This offers symptomatic relief that may help patients cope more steadily with symptom fluctuations and assists with maintaining functional stability. The formulation is also applied in scenarios where additional management of discomfort is required, particularly for pediatric patients and adults with swallowing difficulties, when supportive symptom management is appropriate for chronic care.

---

Quick Fact: Relevant for Episodic Symptom Burdens

Regulatory References

1. NIH MedlinePlus overview of Valproic Acid

The eligibility for using Депакин Хроносфера (Valproate) is strictly defined by regulatory bodies and centers on potential for pregnancy, hepatic status, and age.

Populations for whom use is Contraindicated

Use is absolutely prohibited in patients with:

• Active Liver Disease or significant hepatic dysfunction.
• Urea Cycle Disorders (UCDs).
• Porphyria or known hypersensitivity to the drug.
• Known Mitochondrial Disorders caused by mutations in the POLG gene, or suspected POLG-related disorder in children under two years of age.

Age and Reproductive Status

Population Group	Regulatory Eligibility Status
Pregnant Women	Contraindicated for all indications.
Women of Childbearing Potential	Contraindicated unless strictly compliant with the Pregnancy Prevention Programme (PPP).
Children under 2 years	Not recommended due to a considerably increased risk of fatal hepatotoxicity.
Adolescents	Efficacy for manic episodes in bipolar disorder is not established (under 18 years).
Older Adults	Use requires special caution; initial administration must be reduced due to altered drug elimination.

Eligibility for adults is established for approved indications. Patients with renal impairment may require conditional use due to altered drug elimination, but this is not an absolute contraindication.

Interactions with other medicines and products

This section describes formally documented interaction patterns for Depakine Chronosphere (Valproate) as classified by government regulatory authorities.

---

Formal Interaction Restrictions

Co-administration with Carbapenem Antibiotics (e.g., Meropenem, Ertapenem) is a major restriction due to the rapid and significant reduction in Valproate plasma concentration, which compromises treatment control. This combination is generally contraindicated in regulatory documentation.

---

Pharmacokinetic (Exposure) Alterations

Valproate's metabolism and clearance are subject to several pharmacokinetic interactions.

• Decreased Valproate Exposure: Co-administration with enzyme-inducing medicines, such as Phenytoin, Carbamazepine, and Rifampin, increases Valproate clearance, resulting in a decreased concentration of the medicine in the plasma. Estrogen-containing products also increase Valproate clearance.
• Increased Valproate Exposure: Felbamate and Aspirin (Acetylsalicylic Acid) are associated with increased Valproate levels, either by decreasing clearance or through competition for plasma protein binding.

Valproate also affects other substances. It inhibits the metabolism of drugs like Lamotrigine and Ethosuximide, causing a substantial increase in the plasma concentration of the co-administered drug. Co-administration with substances such as Warfarin may also necessitate adjustment due to altered pharmacokinetics.

---

Pharmacodynamic Effects

A documented pharmacodynamic interaction exists with Topiramate, co-use of which is officially linked to an increased risk of hyperammonemia and encephalopathy. The use of Alcohol or other central nervous system (CNS) depressants results in additive CNS effects, which may increase drowsiness. In geriatric patients, this additive effect carries an elevated risk of somnolence.

The mechanism of action of Депакин Хроносфера is multifaceted, engaging several key biological targets to modulate neuronal excitability.

Dual Modulation of Neuronal Signaling

The compound influences signaling in the Central Nervous System ( CNS) by simultaneously enhancing inhibitory function and restricting excitatory signals. It acts by inhibiting the enzyme GABA Transaminase ( GABA-T), which decreases the metabolic degradation of the inhibitory neurotransmitter GABA, thereby enhancing the inhibitory function of the GABAergic system. Concurrently, it blocks Voltage-Gated Sodium Channels ( VGSCs), preventing rapid ion influx necessary for action potential generation. This dual mechanism contributes to neuronal membrane conditioning and limiting the frequency and amplitude of neuronal action potentials.

Long-Term Gene Regulation (Epigenetic Effects)

A distinct action involves inhibiting Histone Deacetylases ( HDACs). This interaction promotes histone acetylation, leading to altered gene transcription. This epigenetic modulation influences protein synthesis and long-term cellular function, particularly regarding neuronal plasticity.

Physiological Outcome: Restriction of High-Frequency Discharge

The combination of mechanisms restricts the propagation of high-frequency neuronal signaling patterns. By increasing the effectiveness of inhibitory pathways and directly suppressing the firing capability of neurons, the mechanism contributes to a modulated and restricted electrical state within the CNS and raises the threshold for neuronal discharge.

How to Use Депакин Хроносфера: Official Administration Guidelines

Депакин Хроносфера is a prolonged-release granular formulation of valproate, intended strictly for oral administration. The official instructions detail precise steps for preparation, dosing, and schedule to ensure the integrity of the controlled-release mechanism.

---

Official Dosing and Schedule

Category	Principle
Route of Administration	Oral.
Frequency	Once daily or twice daily administration.
Adult Starting Dose	Typically 600 mg daily, increasing by 200 mg at three-day intervals until control is achieved.
Adult Maintenance Dose	Generally 1000 to 2000 mg per day, with the maximum daily dose potentially reaching 2500 mg.

---

Administration Technique and Restrictions

1. Preparation: The granules must be sprinkled onto a small amount of soft food (such as jam, yogurt, or mousse) or stirred into a cold or room temperature drink.
2. Consumption: The mixture must be swallowed immediately and must not be crushed or chewed to preserve the prolonged-release properties.
3. Food Timing: Administration is recommended during meals for consistency, though the timing should remain consistent daily.
4. Handling Restriction: The granules must not be mixed with warm or hot foods or drinks.
5. Dose Integrity: Dosage must be established to the nearest whole sachet, and partial sachets should not be used.

---

Population-Specific Dosing Rules

• Pediatric Patients (over 20 kg): Initial dosage is 400 mg daily, with gradual increases, following weight-based targets.
• Older Adults: The initial dose should be reduced and increased more slowly.
• Missed Dose: If a dose is missed, it should not be compensated for by doubling the next dose.

Research Evidence / Overview of Studies for Депакин Хроносфера (Valproate)

This section provides an overview of the official clinical research and study designs used to evaluate the active substance, valproate, focusing only on the types of evidence that exist according to regulatory and scientific sources.

---

1. Evidence for use in Epilepsy (Various Seizure Types)

The research landscape for valproate in the study of different forms of seizures is structured around Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. Researchers focused on outcomes capturing phases of heightened symptom activity, such as the frequency of seizures and the rate of seizure-free status.

The findings describe patterns observed in the studies related to seizure activity across both generalized seizures and focal seizures. Research highlights changes measured during the study period, which contributes to understanding symptom patterns over time.

While the core evidence is based on many studies, results apply only to the populations studied. Comparative evidence is lacking for a full, long-term assessment compared to other treatments.

---

2. Evidence for use in Acute Manic Episodes (Bipolar Disorder)

Research has explored valproate in acute manic episodes associated with bipolar disorder. The studies conducted during periods of increased symptom activity include short-term, placebo-controlled RCTs and trials comparing valproate against other existing treatments. These trials monitored outcomes related to symptom intensity or variability, typically using standardized rating scales and tracking hospitalization rates.

However, certainty remains low regarding long-term patterns beyond the initial acute phase. The evidence for acute use is well-established only for adults. Data for certain groups, such as children and adolescents, are still emerging.

---

3. What is Still Uncertain in the Research Record

Based on regulatory and peer-reviewed scientific assessments, several limitations exist in the research for valproate. There is limited information for long-term outcomes, as many pivotal studies had follow-up durations that were limited, especially for bipolar maintenance. Comparative evidence is lacking, making it difficult to fully assess the study outcomes compared to other available treatments over an extended timeframe. Research does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted.

Key Studies & References Valproic Acid: Drug Information (MedlinePlus)

Common questions about Депакин Хроносфера (FAQ)

---

Q: Is it necessary to have blood tests while taking the drug?

Official guidance states that monitoring of symptoms and Liver Function Tests (LFTs) is recommended, especially during the first six months of treatment. This is important because of the rare but serious risk of liver damage (hepatotoxicity) associated with the medicine. Regular blood tests are also used to monitor the drug's concentration against established therapeutic levels.

---

Q: Can the drug affect mood or cause anxiety?

Official documents report that the medicine can be associated with changes in mood, including nervousness, agitation, anxiety, and new or worsening depression. Like many medicines that affect the central nervous system, there is also a risk of experiencing suicidal thoughts or tendencies. Official information highlights these potential effects.

---

Q: Are long-term side effects described in official sources?

Official product information describes potential long-term risks, particularly regarding reproductive health. These include risks of severe birth defects and developmental issues if exposure occurs during pregnancy, as well as potential impaired fertility in men. Official documents note that continued specialist review is standard for managing long-term therapy.

---

Q: Why might drowsiness or dizziness occur at the beginning of treatment?

Drowsiness and dizziness are described as common adverse effects that patients may experience, especially when they first start taking the medicine or when the dose is adjusted. This occurrence is generally understood to be related to the drug's initial impact on the central nervous system (CNS). These effects are often temporary as the body adjusts to the treatment.

---

Q: Can Депакин Хроносфера affect memory or concentration?

While memory and concentration issues are not explicitly listed among the most common adverse reactions for adults, the medicine acts on the central nervous system and can cause neurological symptoms. Cognitive impairments and memory problems have been noted in scientific literature and are associated with documented risks for children exposed to the medicine during pregnancy.

---

Q: Why is it necessary to check liver function before starting treatment?

Testing liver function before treatment is part of the required protocol because the medicine is contraindicated, or prohibited, for anyone with active liver disease. Furthermore, checking baseline liver function is a standard measure to determine initial eligibility and address the risk of severe hepatotoxicity, especially within the first six months.

---

Q: What over-the-counter medications can interact with Депакин Хроносфера?

Official interaction data notes that over-the-counter Aspirin (acetylsalicylic acid) can interact with the drug. Aspirin may potentially increase the concentration of the medicine in the blood; this interaction is documented as potentially increasing the medicine's concentration in the blood.

---

Q: Should one continue taking the drug even if symptoms disappeared?

Treatment for conditions like epilepsy is typically long-term, often lasting for many years. Official guidance advises against suddenly stopping the medicine, even if their symptoms are controlled and they feel better, unless a doctor has directed them to do so.

---

Q: Why can't Депакин Хроносфера be stopped abruptly?

Regulatory warnings state that abruptly stopping the medicine can lead to a recurrence of seizures. Stopping suddenly is associated with the risk of precipitating status epilepticus, a condition requiring urgent medical attention, especially when used for major seizures.

---

Q: How long does the course of treatment with this drug usually last?

According to official protocols, continued long-term treatment is generally established after the patient's condition is stabilized and under control. Specialized annual review is noted as standard for managing long-term therapy to ensure continued benefit and safety.

---

Q: Does the active substance of the drug pass into breast milk?

Official information states that the active substance does pass into breast milk, but usually only in low concentrations. Because the full effect on the nursing infant is considered unknown, health authorities note that monitoring the infant is part of the established protocol.

---

Q: How does the drug affect men and their reproductive health?

Official safety alerts indicate that the use of this medicine in men is linked to a potential risk of impaired fertility, which may manifest as lower sperm count or motility. A documented risk of neurodevelopmental disorders in children conceived by men taking the medicine is mentioned in safety information.

---

Q: Is the interaction with antidepressants or tranquilizers described?

Yes, interactions with certain psychotropic medicines are described in official documents. For instance, the medicine may interact with tricyclic antidepressants, which could lead to increased concentrations of the antidepressant in the blood. Official documentation notes that co-administration with other central nervous system depressants is associated with an additive risk of increased drowsiness.

---

Q: Does taking the drug affect the effectiveness of hormonal contraceptives?

Studies suggest that the medicine generally does not reduce the effectiveness of hormonal contraceptives because it is not an enzyme inducer. Regulatory programs outline requirements for the use of highly effective contraception for women of childbearing age due to the high risk of severe birth defects if pregnancy occurs.

Storage and Disposal Requirements

The storage and disposal of Depakine Chronosphere prolonged-release granules must strictly follow the conditions specified in official regulatory labeling to ensure product integrity and safety.

---

Official Storage Requirements

Condition	Requirement
Temperature	Store below 25,^circmathrmC
Protection	Keep in the original package and protect from moisture
Child Safety	Keep out of the sight and reach of children

Handling and Disposal

The medicine must be administered immediately after mixing with food or liquid; the prepared mixture should not be stored for future use. Unused or expired medication, including waste material, must be disposed of in accordance with local requirements for pharmaceutical products.